Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Illumina cuts stake in Grail, strikes deals

by Ann M. Thayer
January 16, 2017 | A version of this story appeared in Volume 95, Issue 3

Illumina intends to reduce its ownership stake in the blood-based cancer detection firm Grail to below 20%. Illumina, a gene sequencing equipment maker, made the decision in light of a potential $1 billion investment in Grail by private investors. Illumina, which created Grail in early 2016 with other investors, says Grail will become one of its largest customers. Separately, Illumina has debuted its NovaSeq gene sequencing technology, which it expects to enable $100 whole genome sequencing. With Bio-Rad, it has launched a new system for single-cell analysis. ­Illumina also has new informatics deals with IBM Watson Health and Philips.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.